Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587962 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
A Phase 1 study, sponsored by Medivir.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02587962: Clinical Trial Phase 1 study, sponsored by Medivir.
NCT02587962 is a Phase 1 study that was terminated before completion, run by Medivir. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02587962, a Phase 1 study, was terminated before completion, sponsored by Medivir.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A dose expansion phase of 4 cohorts will also be included.
Primary Outcome
Evaluation of the safety and tolerability of birinapant when given in combination with pembrolizumab assessed through blood pressure.
Interventions
- DRUG Pembrolizumab
- DRUG Birinapant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-08-04 |
| Est. Completion | 2020-02-17 |
| Phase | Phase 1 |
Why NCT02587962 stopped before completion
NCT02587962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02587962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02587962 about?
NCT02587962 is a clinical study titled "Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors". An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A dose expansion phase of 4 cohorts will also be included.
What is the current status of trial NCT02587962?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-08-04. Estimated completion is 2020-02-17.
What interventions are being tested in trial NCT02587962?
The interventions under investigation include: Pembrolizumab (DRUG), Birinapant (DRUG).
Who is sponsoring clinical trial NCT02587962?
This trial is sponsored by Medivir, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02587962's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI